Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised its ...

Beta Bionics plans to announce Q2 2025 financial results on July 29, followed by a conference call.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010 ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Shares of TD Synnex jumped Tuesday after the IT services provider posted fiscal second-quarter results above analysts' expectations.

Recent discussions on X about Moderna, Inc. (MRNA) have been buzzing with excitement following the company's announcement of positive late-stage trial results for its experimental mRNA-based ...

HealthDay News — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday.